Does a higher AA:EPA ratio indicate a shift toward arachidonic-acid–derived eicosanoid signaling?

An evaluation of the scientific evidence regarding the arachidonic acid (AA) to eicosapentaenoic acid (EPA) ratio reveals the following key insights:

Mechanistic explanations

• Enzyme substrate competition: AA and EPA directly compete for the same metabolic pathways. Specifically, they utilize the same cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) epoxygenase enzymes.
• Metabolic flux steering: Because these enzymes process both fatty acids, their relative abundance in cell membrane phospholipids—the AA:EPA ratio—determines which eicosanoid family dominates. An elevated AA:EPA ratio biases enzyme occupancy toward AA.
• Downstream signaling profiles: This metabolic bias drives the production of 2-series prostaglandins (such as $PGE_2$), thromboxane $A_2$, and 4-series leukotrienes ($LTB_4$). A lower ratio instead shifts production toward 3-series prostaglandins ($PGE_3$), thromboxane $A_3$, 5-series leukotrienes ($LTB_5$), and specialized pro-resolving mediators (SPMs) such as resolvins.

Clinical and physiological evidence

• Dietary intervention dynamics: Clinical studies demonstrate that dietary EPA supplementation significantly alters cellular membrane composition. This reduction in the tissue AA:EPA ratio directly corresponds to a log-linear decrease in pro-inflammatory $PGE_2$ production and a simultaneous increase in EPA-derived alternatives like $PGE_3$ and 12-HEPE.
• Cellular phenotypes: The ratio interacts dynamically with immune cell phenotypes. While pro-inflammatory M1 macrophages preferentially metabolize AA substrates, anti-inflammatory or resolving M2 phenotypes show enhanced conversion of EPA pathways, highlighting how the ratio reflects broader physiological states.

Bottom line

An elevated AA:EPA ratio is a scientifically validated biomarker that directly reflects a metabolic shift toward AA-derived, generally pro-inflammatory eicosanoid signaling over EPA-derived pathways. This shift is driven by direct, concentration-dependent substrate competition for shared COX, LOX, and CYP enzymes.